Patents by Inventor Marco Della Peruta

Marco Della Peruta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD
    Publication number: 20230256093
    Abstract: The present invention provides a method for treating a solid cancer which comprises the step of administering a cell to a subject, wherein the cell comprises a nucleic acid sequence encoding interleukin 12 (IL-12) downstream of a frame-slip motif (FSM) or a translational readthrough motif (TRM).
    Type: Application
    Filed: May 12, 2021
    Publication date: August 17, 2023
    Inventors: Marco Della Peruta, Matteo Righi, Giulia Agliardi, Martin Pulé, Shaun Cordoba, James Sillibourne
  • ROR1 CAR T-cells
    Patent number: 11723925
    Abstract: There is described a chimeric antigen receptor (CAR) which comprises an antigen binding domain which selectively binds to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1), and its use. Also described is a T cell comprising the CAR and its use in the treatment of cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: August 15, 2023
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • ROR1 ANTIBODIES
    Publication number: 20230220073
    Abstract: There is described Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) antibodies that specifically bind a ROR1 polypeptide, and their use. In particular, isolated monoclonal antibodies are described and their use in a number of applications, including in the detection, prevention and treatment of cancer.
    Type: Application
    Filed: July 21, 2022
    Publication date: July 13, 2023
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • ROR1 antibodies
    Patent number: 11466083
    Abstract: There is described Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) antibodies that specifically bind a ROR1 polypeptide, and their use. In particular, isolated monoclonal antibodies are described and their use in a number of applications, including in the detection, prevention and treatment of cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: October 11, 2022
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • BISPECIFIC ANTIBODIES TO ROR1 AND CD3
    Publication number: 20220204621
    Abstract: There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.
    Type: Application
    Filed: March 18, 2022
    Publication date: June 30, 2022
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • Bispecific antibodies to ROR1 and CD3
    Patent number: 11306142
    Abstract: There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: April 19, 2022
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • CAR-T CELLS EXPRESSING AN INHIBITORY ANTI-TGF-BETA-RECEPTOR II SINGLE DOMAIN ANTIBODY
    Publication number: 20210244762
    Abstract: The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) or transgenic T cell receptor (TCR) and secretes an antibody which binds a transforming growth factor beta receptor (T?R).
    Type: Application
    Filed: May 10, 2019
    Publication date: August 12, 2021
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Alex Kinna, Simon Thomas, Mathieu Ferrari, Marco Della Peruta, Phillip Wu
  • CELL
    Publication number: 20210095003
    Abstract: The present invention relates to a cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) a chimeric TNF receptor (TNFR) which comprises (a) a binding domain which is capable of binding a TNFR ligand; and (b) a TNFR signalling domain.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 1, 2021
    Inventors: Martin Pulé, Marco Della Peruta
  • ROR1 CAR T-CELLS
    Publication number: 20200405759
    Abstract: There is described a chimeric antigen receptor (CAR) which comprises an antigen binding domain which selectively binds to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1), and its use. Also described is a T cell comprising the CAR and its use in the treatment of cancer.
    Type: Application
    Filed: July 5, 2018
    Publication date: December 31, 2020
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • ROR1 ANTIBODIES
    Publication number: 20200354448
    Abstract: Thereis described Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) antibodies that specifically bind a ROR1 polypeptide, and their use. In particular, isolated monoclonal antibodies are described and their use in a number of applications, including in the detection, prevention and treatment of cancer.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 12, 2020
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • BISPECIFIC ANTIBODIES TO ROR1 AND CD3
    Publication number: 20200157218
    Abstract: There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.
    Type: Application
    Filed: July 5, 2018
    Publication date: May 21, 2020
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta